RISDIPLAM
risdiplam 750 microgram/mL powder for oral liquid, 80 mL
RISDIPLAM (12609P)
12609P
Manner of administration:Oral
Restriction
Indication: Spinal muscular atrophy (SMA)
Treatment phase: Continuing/maintenance treatment with this drug of either symptomatic Type I, II or
IIIa SMA, or, pre-symptomatic SMA (1 or 2 copies of the SMN2 gene)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $10,890.77 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Evrysdi | |||||